logo
Plus   Neg
Share
Email

Sanofi Data Shows Vaccine Candidate Effective In Dengue Caused By 3 Virus Types

French drugmaker Sanofi's (SNY, SNYNF) vaccines division Sanofi Pasteur late Monday announced the online publication of clinical study results showing that its vaccine candidate protects against dengue fever caused by three dengue virus types.

The results of the world's first efficacy study confirm the safety profile of the dengue vaccine candidate, the firm said. The study results have been published in The Lancet.

Dengue is a mosquito-borne disease caused by four dengue virus serotypes. It is a threat to nearly 3 billion people, especially in some countries of Latin America and Asia.

The full analysis of vaccine efficacy against each serotype, reflecting real-life conditions, showed vaccine efficacy to be 61.2 percent against dengue virus type 1, 81.9 percent against type 3 and 90 percent against type 4.

One of the dengue virus types (serotype 2) eluded the vaccine. Sanofi said analyses are in progress to understand the lack of protection for serotype 2 in the particular epidemiological context of Thailand.

The study was conducted in 4,002 children aged 4 to 11 years, in partnership with the Mahidol University under the patronage of the Thai Ministry of Public Health.

Sanofi Pasteur's dengue vaccine candidate is a live, attenuated vaccine. The vaccination schedule is 3 doses given 6 months apart at 0, 6 and 12 months.

Dr. Scott Halstead, International Vaccine Institute, Seoul, Republic of Korea, said, ''The complexity of dengue virus infection has hampered vaccine research for decades. This is the first time in 50 years of dengue research that I have seen a vaccine that protected a large group of children from clinical disease caused by dengue viruses. Best yet, the vaccine met the highest safety expectations."

Large-scale phase III clinical studies of the dengue vaccine candidate are underway with 31,000 children and adolescents in 10 countries in Asia and Latin 2/3 America. These studies are expected to generate additional data in a broader population and in several epidemiological settings.

Sanofi closed in Paris on Monday lower by 0.65 percent at 65.72 euros on 2.01 million shares.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
InterContinental Hotels Group plc said it will remove plastic straws from its global estate by the end of 2019, representing more than 5,400 hotels in nearly 100 countries. According to the UK-based company, it has already removed plastic straws from nearly 1,000 hotels in its Europe, Middle East, Asia & Africa or EMEAA region. Citigroup Inc. on Friday reported a 12 percent increase in profit for the third quarter from last year, as slightly lower revenues were more than offset by a lower tax rate as well as decline in cost of credit and expenses. Earnings per share beat analysts' expectations, while revenues missed estimates. Citigroup's effective tax rate was 24 percent in the quarter. Walmart Inc. said Thursday that it has formed a joint venture with Eko, a developer of interactive video technology, to develop content that will attract more customers to its digital platforms. The joint venture, known as W*E Interactive Venture, plans to develop original, interactive content for Walmart's website and its Vudu video service. Eko is a company based in New York and Tel Aviv.
Follow RTT